Castleark Management LLC purchased a new stake in Amedisys Inc (NASDAQ:AMED) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 58,500 shares of the health services provider’s stock, valued at approximately $3,674,000. Castleark Management LLC owned 0.17% of Amedisys at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in AMED. Russell Investments Group Ltd. increased its stake in shares of Amedisys by 77.7% in the first quarter. Russell Investments Group Ltd. now owns 36,295 shares of the health services provider’s stock valued at $1,854,000 after purchasing an additional 15,875 shares during the period. Swiss National Bank increased its stake in shares of Amedisys by 1.8% in the first quarter. Swiss National Bank now owns 44,300 shares of the health services provider’s stock valued at $2,263,000 after purchasing an additional 800 shares during the period. UBS Asset Management Americas Inc. increased its stake in shares of Amedisys by 140.0% in the first quarter. UBS Asset Management Americas Inc. now owns 11,760 shares of the health services provider’s stock valued at $601,000 after purchasing an additional 6,861 shares during the period. Karp Capital Management Corp acquired a new stake in shares of Amedisys in the first quarter valued at approximately $683,000. Finally, Ameriprise Financial Inc. increased its stake in shares of Amedisys by 4.8% in the first quarter. Ameriprise Financial Inc. now owns 147,034 shares of the health services provider’s stock valued at $7,511,000 after purchasing an additional 6,674 shares during the period. Institutional investors own 96.55% of the company’s stock.

Several equities research analysts have commented on AMED shares. Mizuho lowered shares of Amedisys from a “buy” rating to a “neutral” rating and set a $50.00 price target on the stock. in a research note on Wednesday, July 26th. Oppenheimer Holdings, Inc. restated a “buy” rating and issued a $60.00 price target on shares of Amedisys in a research note on Friday, September 15th. BidaskClub lowered shares of Amedisys from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 12th. Bank of America Corporation started coverage on shares of Amedisys in a research note on Monday, August 21st. They issued a “neutral” rating and a $55.00 price target on the stock. Finally, SunTrust Banks, Inc. restated a “buy” rating and issued a $60.00 price target on shares of Amedisys in a research note on Monday, October 9th. Seven investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $56.20.

In other Amedisys news, insider David B. Pearce sold 1,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 8th. The shares were sold at an average price of $50.00, for a total value of $50,000.00. Following the completion of the sale, the insider now owns 10,488 shares of the company’s stock, valued at $524,400. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Bruce D. Perkins bought 2,000 shares of the stock in a transaction on Thursday, August 3rd. The stock was purchased at an average cost of $46.60 per share, with a total value of $93,200.00. Following the purchase, the director now directly owns 15,825 shares of the company’s stock, valued at approximately $737,445. The disclosure for this purchase can be found here. Insiders own 2.00% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was posted by Daily Political and is the property of of Daily Political. If you are reading this article on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The original version of this article can be viewed at https://www.dailypolitical.com/2017/10/15/castleark-management-llc-purchases-new-position-in-amedisys-inc-amed.html.

Shares of Amedisys Inc (NASDAQ:AMED) traded down 0.42% during mid-day trading on Friday, reaching $47.80. 323,474 shares of the company were exchanged. The stock has a market capitalization of $1.62 billion, a P/E ratio of 40.85 and a beta of 0.87. Amedisys Inc has a 12 month low of $34.58 and a 12 month high of $65.91. The firm has a 50-day moving average price of $51.89 and a 200 day moving average price of $55.15.

Amedisys (NASDAQ:AMED) last posted its quarterly earnings results on Wednesday, July 26th. The health services provider reported $0.62 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.50 by $0.12. The business had revenue of $378.80 million during the quarter, compared to the consensus estimate of $380.80 million. Amedisys had a net margin of 2.70% and a return on equity of 13.71%. Amedisys’s revenue for the quarter was up 5.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.42 earnings per share. Equities research analysts anticipate that Amedisys Inc will post $2.21 EPS for the current fiscal year.

Amedisys Company Profile

Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.

Want to see what other hedge funds are holding AMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amedisys Inc (NASDAQ:AMED).

Institutional Ownership by Quarter for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with MarketBeat.com's FREE daily email newsletter.